PP_1170x120_10-25-21

Dr. William Larkins

Leucadia Pharmaceuticals launches FDA-approved dihydroergotamine mesylate nasal spray

Leucadia Pharmaceuticals launches FDA-approved dihydroergotamine mesylate nasal spray

CARLSBAD, Calif. – Leucadia Pharmaceuticals, a U.S. innovator of generic drug products and the commercial arm of Custopharm, Inc., announced the launch of its latest first-to-market generic, dihydroergotamine mesylate nasal spray. The FDA-approved nasal spray, now available to patients, is therapeutically equivalent to MIGRANAL and is used for acute treatment of migraine headaches with or